Edition:
United States

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

249.90CHF
14 Dec 2018
Change (% chg)

-- (--)
Prev Close
CHF249.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,496,564
52-wk High
CHF260.35
52-wk Low
CHF206.35

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.97
Market Cap(Mil.): CHF214,033.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.20
Yield (%): 3.31

Financials

  ROG.S Industry Sector
P/E (TTM): 22.03 31.13 34.39
EPS (TTM): 11.25 -- --
ROI: 20.46 15.55 14.96
ROE: 46.88 16.92 16.52

BRIEF-Roche Holding Says EMA Grants Prime Designation For Risdiplam For Treatment Of SMA

* SAYS PRIME DESIGNATION GRANTED BY EUROPEAN MEDICINES AGENCY FOR ROCHE’S RISDIPLAM FOR TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) Source text: https://www.roche.com/media/releases/med-cor-2018-12-17.htm Further company coverage:

1:06am EST

FDA approves Celltrion's biosimilar to Roche's Herceptin

Dec 14 The U.S. Food and Drug Administration on Friday approved South Korean drugmaker Celltrion Inc's biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.

Dec 14 2018

Pfizer's cut-price version of Avastin wins EU panel greenlight

A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin.

Dec 14 2018

Pfizer's cut-price version of Avastin wins EU panel greenlight

Dec 14 A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin.

Dec 14 2018

BRIEF-Roche Collaborates With Merck To Develop Companion Diagnostic Test To Identify Patients Eligible For Anti-Pd-1 Therapy

* ROCHE TO DEVELOP COMPANION DIAGNOSTIC TEST TO HELP IDENTIFY PATIENTS ELIGIBLE FOR ANTI-PD-1 THERAPY BASED ON BIOMARKER EXPRESSION, NOT LOCATION, OF SOLID TUMORS

Dec 11 2018

Gilead Sciences snares Roche veteran O'Day as CEO

Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum.

Dec 10 2018

UPDATE 4-Gilead Sciences snares Roche veteran O'Day as CEO

* William Anderson to replace O'Day as Roche Pharmaceuticals CEO

Dec 10 2018

BRIEF-Roche's Pharmaceuticals Head To Be Replaced By Genentech CEO

* DANIEL O'DAY, CEO ROCHE PHARMACEUTICALS AND MEMBER OF CORPORATE EXECUTIVE COMMITTEE, WILL BE STEPPING DOWN FROM HIS ROLE AS OF 31 DECEMBER 2018

Dec 10 2018

Gilead Sciences to hire Roche executive O'Day as new CEO -source

Dec 9 Drugmaker Gilead Sciences Inc will name Roche Holding AG executive Daniel O'Day as its new chief executive officer, according to a source familiar with the matter.

Dec 09 2018

Roche's lung cancer combo treatment wins FDA approval

Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer.

Dec 07 2018

Earnings vs. Estimates